Mechanism of immune suppression by allogeneic blood transfusion in patients with gastrointestinal cancer.

与未接受同种异体血液的患者相比，接受同种异体血液的患者是否会对生存产生不良影响或术后感染是有争议的。我们回顾性研究胃肠癌根治术患者的生存率：异基因血18例，自体血33例，无输血70例（胃癌66例，结肠癌29例，直肠癌26例），共分析121例癌症患者。比较三组患者的3年生存率；自体输血组的86.3%与未输血组的88.1%相当，但高于同种异体输血组的76.6%，但差异不显著。我们还分析了8例根治性手术患者的免疫标志物、自然杀伤细胞活性和淋巴细胞亚群的变化。但术前、术后、异体、自体、无输血组间无明显差异。总之，输血对癌症患者生存和免疫指标的影响尚未得到证实。需要进行大规模的多中心研究。

Whether allogeneic blood transfusion gives rise to adverse effect on survival or postoperational infection in patients who received allogeneic blood as compared with those who did not received is controversial. We studied retrospetively survival rate in patients who underwent radical operation for gastrointestinal cancer : 18 allogeneic blood, 33 autologous blood, and 70 no blood transfusion (66 gastric cancer, 29 colon cancer, and 26 rectal cancer), a total of 121 cancer patients were analyzed. We compared 3-year survival rate of the three patient groups ; 86.3% in autologous transfusion group was comparable with 88.1% of no transfusion group but higher, although not significantly, than 76.6% in allogeneic transfusion group. We also analyzed the change of immunological markers, natural killer cell activities and lymphocyte subsets in 8 patients undergoing radical operation. However, we could not find any significant differences among before nad after operation, and among the groups of allogeneic, autologous, and no transfusion. In conclusion, the effects of blood transfusion on survival and immunological markers of the patients with cancer were not demonstrated. A large-scale multi-center study is warranted.